Form 4: Glaukos Corp President & COO Joseph E. Gilliam Reports Stock Option Exercises and Sales

Joseph E. Gilliam, President & COO of Glaukos Corporation, exercised stock options and sold shares of common stock on February 23, 2024, according to a Form 4 filing with the SEC.

Summary

• On February 23, 2024, Joseph E. Gilliam, the President & COO of Glaukos Corporation, engaged in multiple transactions involving the company's common stock.
• Gilliam exercised stock options to acquire 26,671 shares at $39.10, 74,425 shares at $41.69, 13,128 shares at $30.92, and 4,607 shares at $39.10.
• Concurrently, Gilliam sold 21,414 shares at a weighted average price of $90.94 (ranging from $90.37 to $91.02), 114,739 shares at a weighted average price of $92.33 (ranging from $91.79 to $92.76), and 4,092 shares at a weighted average price of $93.05 (ranging from $92.80 to $93.45).
• Following these transactions, Gilliam directly owns 98,388 shares of Glaukos Corp common stock, taking into account 81,885 restricted stock units that have not yet vested or been delivered.
• The reported amount of derivative securities beneficially owned takes into account a reconciliation adjustment to reflect the Reporting Person's economic interest in the shares underlying this stock option grant to comply with the terms of a domestic relations order issued in connection with a marital dissolution.
• An adjustment of 5,000 shares underlying a stock option grant reported as exercised on a Form 4 filed with the Securities and Exchange Commission on February 12, 2024 was made.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company executives. It is common for executives to exercise stock options and sell shares for personal financial management.

Comparison to Industry Standards

• Monitoring insider transactions is a standard practice in corporate governance and financial markets.
• Companies like Alcon (ALC), Johnson & Johnson (JNJ), and Novartis (NVS) in the ophthalmic industry are also subject to similar insider trading regulations and reporting requirements.
• The disclosed transactions are typical for executives holding stock options as part of their compensation packages.

Stakeholder Impact

• Shareholders are informed about insider transactions, which can influence their perception of the company's stock.
• The transactions may have a minor impact on the stock's trading volume and price.

Key Dates